SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " therapy " 578 found 🔀 AI-powered Shuffle
Paris Jackson opens up about ‘painful’ electroconvulsive therapy. She’s not alone
Women are still being treated with electroconvulsive therapy, including Paris Jackson. A new study shows that women face the most side effects.
Medicaid Psychotherapy Spending Up 156%
This is an exclusive BHB+ article Medicaid spending on core psychotherapy services has more than doubled from 2018 to 2024, according to Behavioral Health
General Catalyst’s Health System Places Its Tech Bets
In this week’s edition of InnovationRx, we look at Summa Health’s first tech bets, the healthcare leaders on Forbes Veteran 250 list, BioMarin’s acquisition of an early-stage bone disease therapy, and more.
Scientists turn probiotic bacteria into tiny drug factories for pancreatic cancer
Engineered probiotic bacteria were able to infiltrate pancreatic tumors, stimulate cancer-fighting immune cells, and slow tumor growth in animal studies. Even more strikingly, the treatment worked better when combined with chemotherapy, radiation, or immunotherapy.
Trump is taking credit for sharply declining drug prices. The reality is more complex
New federal data that shows U.S. prescription drug prices fell 0.8% in July and are down 3.1% from a year ago, the steepest year-over-year drop since 1963.
Tackling rare genetic disorders with patient-focused science
At MIT’s McGovern Institute for Brain Research, PhD candidate Shannon Knight is developing a novel gene therapy to tackle rare genetic conditions such as SYNGAP1 disorder.
A therapy that “rewrites” childhood memories can ease fear of failure
Childhood criticism can leave people carrying a fear of failure long into adulthood, but new research suggests those emotional patterns may be surprisingly flexible. Young adults who revisited painful memories through imagery-based therapy showed lasting reductions in fear, guilt, sadness, and stress.
Is hormone therapy the cheat code to perimenopause?
Perimenopause can be overwhelming. Mood swings, insomnia and hot flashes can make you feel like a completely different person. Hormone therapy is one way a lot of women are treating the symptoms. Life Kit’s Marielle Segarra talks with Dr. Mara Gordon of NPR’s Real Talk with a Doc column about the risks and benefits.Follow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
Maternal genes enable trophoblastic tumor relapse after immunotherapy
Cell-to-cell transfer of maternal genetic material may provide trophoblastic tumor cells with new functions.
Nabil Chehab: “What Science Can Do” - Advancing Next-Generation Cell Therapies
Nabil Chehab: “What Science Can Do” - Advancing Next-Generation Cell Therapies / AstraZeneca, cancer, Cell Therapy, Nabil Chehab, OncoDaily, Oncology
The Trouble with the Soft Sciences
The tale of Jason Arday is a reminder of how today’s social scientists often care little about seeking the truth.
IV therapy and wellness service business celebrates grand opening
“We want to provide the best care possible," said its chief operating officer.
IV therapy and wellness business opens
Valley Vital Care of Charleston celebrated its grand opening with a ribbon-cutting ceremony on Thursday.
CRISPR roadblocks: Scientists identify genes blocking gene therapy success
Like a delivery driver navigating crowded city streets, a gene-therapy-toting lipid nanoparticle faces a gauntlet of potential detours on its journey toward a cell's nucleus. First, there's entering the ...
Small Business Spotlight: Specialty dental practice takes root on Market St.
WHAT MADE YOU WANT TO OPEN BLUE HERON ROOT CANAL SPECIALISTS? OWNER SARAH ERMOSHKIN: “I’ve always been an entrepreneur at heart. When I was 23 years old, I owned a cafe in Seattle, where I even fought to oppose oppressive sales taxes on espresso drinks. After selling that business, I got married and started a family. Once my children were in school, I attended dental school through the Navy Health Professions Scholarship Program (HPSP), which covered my tuition and provided a stipend. From the beginning, my goal was to eventually own my own practice after completing my military service. The work I do is incredibly rewarding and being able to create an environment that puts patients first while helping employees grow professionally makes every day as a business owner meaningful.” WHAT DOES YOUR BUSINESS PROVIDE? ERMOSHKIN: “Endodontists are often called ‘pain doctors’ because our primary mission is to relieve pain and save natural teeth. We specialize in root canal therapy, retreatment of nonhealing root canals, treatment of root resorption, apicoectomies – microsurgical root-end procedures – and vital pulp therapy for children. Our goal is to preserve teeth that might otherwise need to be extracted and replaced with implants. Saving a patient’s natural tooth is almost always the best long-term solution for their oral health.” HOW DOES YOUR MILITARY TRAINING HELP YOUR BUSINESS? ERMOSHKIN: “My military service taught me how to lead, collaborate and make decisions under pressure. I worked closely with senior leadership while treating a large patient population and collaborating with specialists across multiple disciplines. During the COVID-19 pandemic, (I) served a dual role as Navy dentist and as the public affairs officer for Naval Health Clinic Annapolis, where I helped develop medical and dental communications for the midshipmen and support staff, while coordinating with the broader Navy Capital Region. We worked closely with other military treatment facilities to share best practices and deliver consistent public health messaging. Those leadership experiences continue to shape how I lead my team and serve our patients today.” WHAT CHALLENGES ARE YOU FACING RIGHT NOW IN YOUR BUSINESS? ERMOSHKIN: “One of our biggest challenges is overcoming the misinformation surrounding root canal treatment. Root canals are safe, effective and often the best way to relieve pain while preserving a natural tooth. Unfortunately, many people choose extraction because they believe it’s less expensive or because they’ve seen misleading information online. What they may not realize is that losing a tooth can lead to shifting teeth, changes in the way they bite and chew and significantly higher costs to restore their smile later.”
US bars federal funding of gender-affirming care for low-income minors
WASHINGTON, Aug 11 (Reuters) - The Trump administration finalized a rule on Tuesday barring two major federal health programs from funding puberty blockers, hormone therapy and surgeries to treat gend...
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Who really needs testosterone?
The military plans to start screening service members for low testosterone, and social media is overflowing with claims about testosterone therapy. But who actually needs it?
Everyone's talking about hormone therapy for menopause. Should I be on it?
For years doctors advised women against hormone therapy for women in the menopausal transition. Now everyone's talking about how great it is. Is it really a wonder drug that women should all be on?
Vanderbilt Health physical therapist bound for Nationals after winning four medals at Tennessee Senior Olympics
Vanderbilt Health physical therapist Grant Schlisner, PT, DPT, Cert. MDT, won four medals in the recent Tennessee Senior Olympics, which qualifies him to compete in the national Senior Olympics, set for July 2027 in Tulsa, Oklahoma. Senior Olympians are athletes 50 years or older who compete in regional events for an opportunity to move to state events, and eventually to the Nationals. Schlisner’s medals were in the javelin, discus and softball throw (gold) and shot put (bronze). Schlisner, who is based at Vanderbilt Health One Hundred Oaks, grew up in the Chattanooga area in a family that valued physical fitness and playing sports, and he says, with considerable understatement, “The whole family is quite athletic.” Grant Schlisner (R) with brother Bret and sister Sue, all of whom won medals in the Tennessee State Senior Olympics. (photo courtesy Grant Schlisner) His brother Bret also competed in the Senior Olympics. So did his sister Sue. (His other sister Tammy did not compete, but, Schlisner said, “We’re still going to work on her.”) And their father, who now lives in South Dakota, competed in that state’s Senior Olympics in the category for athletes aged 84 to 89. Schlisner was a high school athlete in several sports, including stints as a baseball pitcher and a football quarterback. Since he was already playing positions in other sports in which he was throwing things, he was also recruited to the school’s track and field team, which is where he gained experience in the events that were his ticket to the 2027 Nationals. The medals are a reward for the hard work of training and preparation, but Schlisner said the real reward is the fitness that the medals represent. Schlisner competes in one of his medal-winning events, the shot put. (photo courtesy Grant Schlisner) “[Preparing for competition] got me working out to train for these events. I added more extensive weight training to promote injury prevention and building flexibility and strength have made me feel better overall.” He also said that, in addition to the physical rewards, he enjoys the camaraderie of the other athletes and a feeling of accomplishment. “It’s great to be able to have a goal,” he said. “If you aim low, you’ll hit it. This is aiming high. I want to bring home a medal in the Nationals.” His physical therapy patients, especially those who may be discouraged or need a little extra motivation, also benefit from his example. “I can connect with patients and say, ‘I’m 57 with previous injuries, and I’ve been doing these events, and you can get back to your ‘sport’ as well, whether that is chasing grandkids or participating in a competitive activity,’” he said. And being around the other Senior Olympians, especially in the older age groups, is motivating for him, as well. “One competitor was 90 years old,” he said. “She’s not just sitting around. That was super motivating and cool to see. I don’t want to be a lump on the couch at 90.”
As AI 'therapists' dish out advice, California lawmakers try to set some limits
A new bill would stop companies from marketing chatbots as therapy and force stricter oversight of AI in mental health care — as a labor union wages a parallel fight against Kaiser Permanente.
700-acre motor sports park in Powhatan gets thumbs-down from planning commission
“It’s not going to stay a 700-acre hunting property forever,” said Throttle Therapy owner Scott McAdoo. “We’re just trying to keep Powhatan rural by supporting outdoor recreation.”
Clopidogrel monotherapy bests aspirin when patients with diabetes undergo PCI
After an initial period of DAPT, what's the best next step? A new analysis reviewed data from the SMART-CHOICE 3 clinical trial.
Essentia Health, Park Avenue Therapies announce collaboration in Cloquet
Essentia Health is excited to announce it will purchase the therapy practice of Park Avenue Therapies, a longtime community pillar in Cloquet.
CVS Health enhances its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications
CVS Health® today announced a revamp of its weight management program, making it easier for eligible adults to access clinical care, navigate medication costs and get ongoing support for GLP-1 therapy.
AI generates personalized radiopharmaceutical therapy doses in under 23 seconds
The model has the potential to improve upon the one-size-fits-all dosing approach used for most RPT prostate cancer treatments.
The Beauty Of Settled Science
Commenters convinced me I made a subtle mis-step in my framing of Psychology Research Is Mostly Fine. My framing emphasized that social priming studies had failed to replicate, but that many other subfields of psychology hadn’t. This naturally led commenters to point to failed replications in other subfields. Although none of these were as bad as social priming, few or none were entirely problem-free. Instead of emphasizing the difference between social priming and other subfields, I should have emphasized the difference between settled science and novel research. Here are some of my favorite psychology findings: The brain is sculpted by reinforcement learning, and a key driver of this learning is a prediction-error-based algorithm located in the nucleus accumbens and implemented through dopamine. Psychedelic drugs exert their effects through 5-HT2A receptors, pointing to a role for these receptors in some sort of construct like the balance between priors and new evidence. Certain cognitive functions are localized to certain brain areas (for example, impulse control to the frontal lobes; linguistic structure to Broca’s area, linguistic meaning to Wernicke’s area. But injure one of these areas, or render a certain function useless (eg a blind person having no more use for their visual cortex), and these mappings can gradually shift - suggesting that neurons are general-purpose compute whose specialization is a contingent fact about convenience and efficiency rather than a necessity. Most personality traits and general capabilities are about 50% genetic and 50% random, with little role for family environment or childhood history, with a few notable exceptions like partisan preference. Recent research complicates this story, but the further you go from this basic picture, the gnarlier the chains of indirect causation you require. Neurons fire together in “brain waves”, whose exact frequency corresponds with the character of consciousness; These divide neurons into natural subpopulations and linked graphs. The gamma rhythm corresponds surprisingly well to items in conscious awareness. GABA receptors seem to be involved in something like relaxation. By hitting different GABA receptors in different ways, you can modulate the exact type of relaxation you produce. Hitting GABA-A directly is too powerful and can cause dangerous levels of sedation, but allosteric modulation of GABA is an incredibly fruitful strategy that underlies drugs from benzos to barbituates to alcohol. If you know your GABA-A subunits, you can target specific subtypes of relaxation; for example, Ambien hits GABA-A1 and induces sleep. Memory divides somewhat fuzzily into bins of immediate-sensory, short-term, and long-term, with separate retrieval and storage functions, and separate systems for declarative vs. procedural learning. These can be harmed selectively, usually by hippocampal injury, so that some patients can remember their life stories but not form new long-term memories, or learn new skills like bike-riding but not new facts. The exact substrate of memory is unclear but seems to involve new synaptic connections between neurons in at least some way. The ability of modern psychology and psychiatry to treat mental illness is real but limited. SSRIs work for half or slightly fewer than half of patients; antipsychotics work with extreme side effects; benzodiazpines work but produce addiction and tolerance in many (not all) people. Most supplements are stuck in Poor Quality Study Replication Crisis Hell, but melatonin and l-theanine stand out as especially promising. Psychotherapy works with moderate effect size, but (with a few exceptions) seems to be more about the relationship with the provider than the details of the therapy itself. Mental hospitalization can sometimes defuse immediate crises but work less well than mental hospitals would like, with some studies showing overall negative effects. Schizophrenia is mostly genetic, but risk also increases with prenatal infection (especially rubella) and obstetric complications; there is suggestive evidence for roles of social stress and drug use (with psychedelics and marijuana making things worse, and nicotine if anything making things better). Bipolar and schizophrenia are so closely linked on a pathophysiological level that it seems like they might be the same disease; on the clinical level, they do seem to follow two separate courses/prognoses but can sometimes surprise clinicians by eg someone who seemed condemned to permanent schizophrenia unexpectedly recovering. The brain’s native reinforcement learning algorithms cash out in the phenomena of classical and operant conditioning; different reinforcement schedules reinforce at different levels, which can be exploited by bad actors to make especially compelling products (eg slot machines). None of these are immune to doubt. A few are speculative; one or two are genuinely unorthodox. But they’re all a step above one p = 0.049 paper that might not replicate. If they get overturned, they’ll be overturned by the same sort of genuine scientific shift that replaced Ptolemy with Copernicus or Lamarck with Darwin, not some sort of sordid discovery about someone entering random numbers into a spreadsheet. In 2008, Eliezer Yudkowsky wrote about The Beauty Of Settled Science: If you only care about scientific issues that are controversial, you will end up with a head stuffed full of garbage. The media thinks that only the cutting edge of science is worth reporting on. How often do you see headlines like “General Relativity still governing planetary orbits” or “Phlogiston theory remains false”? So, by the time anything is solid science, it is no longer a breaking headline. “Newsworthy” science is often based on the thinnest of evidence and wrong half the time—if it were not on the uttermost fringes of the scientific frontier, it would not be breaking news. Scientific controversies are problems so difficult that even people who’ve spent years mastering the field can still fool themselves. That’s what makes for the heated arguments that attract all the media attention. Worse, if you aren’t in the field and part of the game, controversies aren’t even fun. Don’t be embarrassed to read elementary science textbooks, either. If you want to pretend to be sophisticated, go find a play to sneer at. If you just want to have fun, remember that simplicity is at the core of scientific beauty [...] A steady diet of science news is bad for you: You are what you eat, and if you eat only science reporting on fluid situations, without a solid textbook now and then, your brain will turn to liquid. Psychology isn’t centrally the new paper in Annals Of Recently-Breaking News saying that an n=5 study showing that large portion sizes increase support for terrorism. Psychology is centrally ideas like brain waves, GABA receptors, reinforcement learning, twin studies, and connectionism. People who think differently are worrying too much about BREAKING NEWS!!!, and should stop. The key distinction isn’t “recent research in social psychology” vs. “recent research in cognitive/bio/behavioral psychology”, as my essay last week unfortunately implied. It’s recent research in general vs. the deposit of settled science, battle-tested hypotheses, and carefully-earmarked speculation. And part of the reason social priming in particular was such a disaster was that it defied that heuristic, building itself up over hundreds of studies until it approached or even entered the pantheon of settled science - before collapsing (5-HTTLPR was also sort of like this). This isn’t a claim that settled science is always right - Freud was “settled science” for a long time - just that there’s an intuitive distinction between the level of credence you should have in the existence of power posing vs. the existence of Broca’s Area. (I compounded this error by calling the last post “Psychology Research Is Mostly Fine”, which suggested I was talking about the new research rather than the settled science. I actually meant to distinguish between research-psychology-the-field vs. clinical-psychology-aka-therapy, but this framing unintentionally pushed against the point I wanted to make) Some commenters on the previous article understood this point, but challenged its weight. It’s very cool, they said, to know how many neurons are in which brain lobe, but the main way that Psychology affected their lives was through bad clickbait studies used to buttress dumb policies; some p = 0.049 study says that exposure to microaggressions makes minorities’ brains shrivel into raisins, and now their company has to implement punitive DEI or be sued for hazardous work conditions. I won’t dispute this as an accurate description of how the sausage gets made, but it’s worth examining the trains of thought that connect this observation to a campaign against psychology in general: The dumb woke psychology was wrong and bad, and I don’t have good heuristics for distinguishing dumb woke psychology from other psychology, so I’m going to assume it’s all wrong and bad. The dumb woke psychology was wrong and bad; it seems useful to punish/discredit psychology as a whole to assist my campaign against it, so for propaganda purposes I will try to discredit psychology as a whole. To people in the first camp, my response is: come on, your heuristics aren’t that bad. “Microaggressions makes minorities’ brains shrivel up like raisins” is in the woke category; “the hippocampal theta rhythm seems to be associated with both memory and pathfinding, suggesting an unexpected yet surprisingly compelling relationship between the two” is in the not-woke category, don’t play dumb here. To people in the second camp, my response is: deliberately exaggerated propaganda campaigns are bad and this is a confession, not an excuse. Inability to view science through anything but a political lens was what got us into this problem; doubling down on it is a temporary solution but a recipe for permanent disaster. If you pronounce entire fields of science to be acceptable collateral damage in your campaign against bad political actors, you will alienate not just scientists but patients, clinicians, and general lovers of truth. Instead, you can say the thing you mean - that woke partisans shouldn’t try to occupy and exploit the otherwise-noble science of psychology for their own political gain - and wage the same campaign with a halo rather than a comic-book-villain goatee. From the font of oracular wisdom that is Weird Sun Twitter: [ Vessel Of Spirit@VesselOfSpirit i love you all conditionally but i love the good part of you unconditionally. even if it becomes a very small part 2:11 AM · Jan 22, 2015 1 Reply · 5 Reposts · 29 Likes ](https://x.com/VesselOfSpirit/status/558084551772471298) This is how I feel about psychology1, too, but with a touch more optimism. The good part of psychology is enormous, a hoard of endless treasures. You just have to look past the headlines! 1 To play devil’s advocate - should one always be so magnamious? Astrology? Phrenology? These seem different in that their entire orientation was flawed from the start; they didn’t simply fail to find the correct constellation-personality connections, the whole project of searching for connections between constellations and personality was doomed from the start. More difficult might be asking the same question about education research, which is notoriously bad. I don’t know enough about education research to know if there’s some settled science of correct and enlightening results lurking in the background beyond the day-to-day froth of poorly-conducted and politically-motivated studies. I think if it’s 90% bad, 10% good, it’s correct to call it bad as a compact way of communicating a useful truth; I think psychology is better than that, but admit it’s a tough judgment call.
A common sugar may help cancer cells break free and spread
Chemotherapy-surviving ovarian cancer cells may release fructose to help neighboring tumor cells loosen, escape, and spread. The discovery suggests that sugary diets and cholesterol-lowering drugs could influence cancer progression, though the effects have not yet been confirmed in patients.
Beyond crayons: Art therapy tackles youth mental health crisis here
Program leaders report seeing students develop a sense of belonging, confidence and resilience.
Opinion | Therapy should be a safe place for everyone, including Zionists
Mental health professionals and patients have report uptick in anti-Israel activism spilling over into medical settings.
Does public health *need* MAHA?
Last week, our friend Dr. Craig Spencer sparked an ongoing volatile discussion with his Atlantic article “Public Health Needs MAHA.” Some have come out in strong dissent, others are cheering, and others are simply lamenting that we find ourselves in such a divided world to begin with. We will dare to dip our toes in these controversial waters, too. Does public health need MAHA? We think in some ways yes, and in other ways, no. MAHA leaders versus the everyday MAHA supporter The vitriol in this debate mostly comes from one collapsed distinction: the leadership of MAHA is not necessarily the same as the people who support it. Say “MAHA” and most people picture RFK Jr. Fair enough, as he coined the term and holds most of the power. And, yes, some MAHA followers treat Kennedy as something close to a saint. But talk to the grassroots, and it’s not a monolith. They’re Republicans, Democrats, and Independents. People who distrust vaccines and vaccine supporters. It’s a wide, eclectic coalition. The data backs this too: 4 in 10 Americans support the movement—that’s a lot of people! But according to polls, vaccines and medical choice (the issues most tied to Kennedy personally) are cited by only 4% as their reason for supporting the movement. For many, the motivations are much broader. Many MAHA supporters are signing up for the idea that “something needs to change” with health in this country. They’re asking good-faith questions about corporate influence on our health systems, health care costs, nutrition, chemicals, and clean air and water. These are all questions that plenty of public health professionals recognize as legitimate and also care about very deeply. Blurring the lines between the leadership and grassroots does real damage in two important ways: It hands the 4 in 10 exactly the narrative already fed—that the health ecosystem doesn’t listen, doesn’t care, and paints every critic with the same brush. It gives the actual bad actor more power. RFK Jr. has done irreparable damage and can’t be trusted. What the MAHA movement gets right A healthy population is something the public health field was literally built on, and many of these topics are things we have dedicated our lives to. Yet the MAHA movement has captivated nearly half the country in a way the public health establishment has failed to achieve. So that means MAHA is doing something right. Some of it may be timing (after a Covid-19 pandemic and deep frustration and mistrust with institutions). The movement also does three other things really well: 1. It gives a new, louder voice to system failures. While MAHA is not a monolith, one theme stays consistent across their stories: the system failed them. For some, it was the system that flooded their communities with opioids and then walked away. For others, it was the system that let their business collapse during Covid with no safety net in sight. For others still, it was the system that failed to help them manage a complex chronic illness, bouncing them from physician to physician without any real answers. And in many ways, our health ecosystems are failing Americans. Why are medical bills so incomprehensible? Why do some kids get a healthy school lunch and others don’t? Why do an epidemiologist and a MD/PhD student have to start newsletters in the middle of the biggest public health emergency in a century, just so people can get straight information? Because the systems failed. This deep-seated frustration driving many Americans to search for solutions elsewhere needs to be recognized. 2. MAHA has brilliant comms central to their efforts. MAHA figured out something most health institutions still have not: the information landscape changed. It’s participatory now, not top-down; influence runs through many nodes in a community, not one institution; and storytelling and telling audiences “what you really think” moves people more than data dumps do. MAHA goes where audiences are listening, using podcasts, social media, and memes in ways most health institutions would scoff at—but it works. 3. They are very good at organizing. A MAHA meeting feels like a rally: energy, speakers, music, and most importantly, an action for everyone. Someone’s writing the next policy brief, someone’s seeding a narrative, someone knows the next legislative deadline, someone’s sending the text messages for a campaign. None of this is new (ask the civil rights movement), but MAHA knows it works and has capitalized on it. What MAHA gets wrong This list could be much longer, and this newsletter has spent a lot of time covering it, but here are a few things: Poor use of scientific evidence. This is the fundamental problem with many MAHA policies: the hype outpaces the science, and experts are often villainized for pointing this out. MAHA leadership has traded real solutions for cheap wins. For example, instead of taking on the powerful food industry and passing real reforms, it has celebrated french fries made of beef tallow and taken out artificial dyes from still very sugary children’s cereal. These changes won’t move the needle on America’s diet. MAHA leadership has tried to dismantle vaccine access in the U.S. While many MAHA supporters emphasize other issues, the effort to change vaccine policy has become MAHA’s signature effort. This is not surprising given RFK Jr.’s extensive track record campaigning against vaccines. It has rallied behind the wrong leader. RFK Jr. has a decades-long track record of villifying doctors, scientists, and public health workers, well before he became HHS secretary. He is known for his decades-long work sowing distrust in vaccines as well as life-saving treatments like antiretroviral therapy for HIV. This is not a serious person who can move the needle on health in the U.S, and he has already done serious damage. Public health needs more than defense Defending the evidence is absolutely necessary so health in the U.S. doesn’t move further backward. The public health establishment is very good at defense. The problem is this defense often sounds like defending the status quo, which has failed many people. Public health needs to offer an alternative to RFK Jr.’s MAHA—one that is rooted in evidence, truly listens to and addresses people’s frustrations, and has innovative solutions and the courage to change the systems. How do we get there? Find common ground. Do you know what most people care most about? The abysmal cost of healthcare. Start there. Fight for the human loudly. Too often, communications and engagement center on science with a capital S, funding mechanisms, or the CDC/FDA/NIH. Not the person. So the public doesn’t see themselves in it. Instead, they see people fighting for the very powerful systems that they feel negatively impact their health and well-being. Let the public feel and hear that you see their frustrations, you get it, and you’re fighting for them within the system. Recognize when pro-science messages are alienating people. Facts absolutely matter, but angrily venting only alienates people further. Our friend Elisabeth Marnik recently wrote a New York Times article about her experience growing up unvaccinated and how listening and empathetic conversation are the only ways to reach people that really work (a position backed by communication science). Her comments section was full of hateful comments from pro-vaccine individuals attacking her for daring to suggest we approach vaccine-hesitant individuals with empathy. It is possible to both stand firm behind scientific evidence and empathize with people who don’t trust it. Lean into politics smartly. Often, public health has shied away from politics: Don’t touch it, lest you get burned. But this fails to recognize that the third rail is what fuels the train: who is elected determines our budgets, our priorities, and our authority. Being political means being very savvy in strategy on both sides of the aisle, knowing your audience, and recognizing that political capital is as scarce as financial resources and needs to be allocated accordingly. Bottom line So does public health need MAHA? That’s not really the right question. Public health has a responsibility not to dismiss 40% of the country who feel heard by this movement and are frustrated that the system has failed them. And it has a responsibility to stick to the evidence and recognize MAHA leadership for what it is: a danger to our nation’s health. Both can, and should, be done. Love, YLE and KP A big thanks to Craig Spencer, who had the courage to put his neck out there to start a much-needed discussion at such a critical moment—one that is determining the identity of an entire field. Kristen Panthagani, MD, PhD is completing an emergency medicine residency and research fellowship focusing on health literacy and communication. In her free time, she writes the newsletters You Can Know Things debunking health myths and rumors and The Public Health Roundup. Views expressed belong to KP, not her employer. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. The YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
Mercer students provide behavioral healthcare to farmworkers
Earlier this summer, Mercer University School of Medicine (MUSM) faculty and Master of Family Therapy (MFT) students participated in the Georgia Farmworker Family Health Program.
South Florida Medicaid families say kids with autism are losing therapy as state cuts and insurer pause add up
Critics call Trump admin's testosterone replacement therapy 'hypocritical'
The Trump administration announced earlier this month that it is offering supplemental testosterone replacement therapy for men currently serving in the military that are 30 and older. But critics call it "hypocrisy," as the administration kicks out transgender troops.
U.S. states are all over the map on how to regulate AI therapy chatbots
Six states have split four ways on regulating AI therapy chatbots. The same product can be legal in one place and criminally exposed in another
Journal, university investigations launched into gene-editing death following Science-Retraction Watch reporting
Nature is investigating concerns surrounding a paper at the heart of a news story published last week on the death of a 6-year-old girl following a gene therapy treatment in China. The paper, publi…
Flawed studies linking hormone therapy to breast cancer made doctors reluctant to prescribe it for menopause relief – especially for breast cancer survivors
Menopausal hormone therapy no longer has the highest-level warning label about the risk of breast cancer, opening a gray area on who would benefit most from treatment.
Florida urges doctors not to prescribe mental health medication for children
Florida's surgeon general has warned doctors not to prescribe antidepressants and other psych drugs for children, instead urging comprehensive evaluations and behavioral therapy as first line treatment options.
Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?
Last week, the Pentagon posted a video on X announcing they will be mandating testosterone screening for troops in the military aged 30 and above. If they test low, they will be offered voluntary testosterone replacement therapy. This episode is available on Apple Podcasts, Spotify, and Youtube. At the same time, FDA has announced it […]
National healthcare groups join HHS effort to improve behavioral health, addiction care
The Health and Human Services Secretary today announced that dozens of insurers, medical societies, healthcare providers and behavioral health experts have pledged to strengthen the nation’s behavioral health system by advancing best practices aimed at improving mental health and addiction treatment.
Orlando Health's pet therapy program offers comfort to patients and families
Orlando Health's growing Paws for Hope pet therapy program, supported by volunteers and donations, provides emotional support to patients, families, and staff through trained therapy dogs and their handlers.
What Health Informatics Means in Physical Therapy
Physical therapists are well positioned to use informatics to improve education, communication and patient-centered care.
UW Health becomes one of select few centers in nation offering proton therapy
MADISON — UW Health has joined an exclusive group of medical centers across the country by opening a proton therapy facility, eliminating the need for Wisconsin patients to travel to
How brain cells restore healthy growth and connections after a disease-causing genetic deletion
Scientists at Virginia Tech's Fralin Biomedical Research Institute at VTC have discovered how an experimental therapy can help brain cells overcome the effects of a disease-causing genetic deletion. Instead ...
Biodegradable implant can deliver targeted cancer immunotherapy while protecting healthy tissue
Scientists at Houston Methodist Research Institute have developed a biodegradable implant designed to deliver cancer-fighting immunotherapy drugs directly into tumors over an extended period, a strategy ...
The biohacking sauna blanket Gwyneth Paltrow calls a '10 out of 10' is $140 off at Nordstrom
Fans of the infrared heat therapy also include Kate Hudson and Miranda Kerr.
McConnell releases health update, saying he’s not ready to return to work yet
McConnell has missed the last 38 votes on the Senate floor since his hospitalization on June 14. His said he’s undergoing “intense physical therapy” but didn’t offer a timeline for his return.
UT Health San Antonio uncovers potential strategy for safer cancer treatments
Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu Content provided by Claire Kowalick SAN ANTONIO, July 27, 2026 – Scientists at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), have found a potential path to maintaining the cancer-fighting benefits of one type of immunotherapy while limiting harmful […]
Stanford lecturer says red light therapy has real science behind it — but not every device works
Red light therapy has become a fixture on social media, with influencers claiming it can improve skin, reduce pain and speed recovery. Rachele Pojednic, faculty at Stanford University and chief science officer at Restore Hyper Wellness, said the science behind it is more solid than many people assume.
Red Light Therapy - social media fad or real science?
Red light therapy has become a fixture on social media, with influencers claiming it can improve skin, reduce pain and speed recovery. Rachele Pojednic, faculty at Stanford University and chief science officer at Restore Hyper Wellness, said the science behind it is more solid than many people assume.
Chinese scientist faces probe after girl dies ‘after experimental gene therapy’
Shanghai Jiao Tong University says it is investigating after a report alleges the child died after receiving treatment from Qiu Zilong.
Science & Medicine: Spinal cord injury and walking again
Selina Morgan holds a doctorate in physical therapy, a board certification in neurological physical therapy, and is an assistant professor in the Department of Physical Therapy at UT Health San Antonio. She believes that there are thousands of people out there in wheelchairs who don’t have to be.
A daily fiber supplement reduced knee arthritis pain and improved strength
A prebiotic fiber supplement reduced knee osteoarthritis pain while also improving grip strength and pain sensitivity in a six-week trial. The results hint at a fascinating gut-muscle-pain connection and suggest that a simple daily supplement may be easier to maintain than digital physiotherapy.
Addressing adolescence mental health through creativity
Through its partnership with the Boys and Girls Club of the Twin Cities, Blue Cross and Blue Shield of Minnesota is helping teens harness the power of art therapy to achieve better mental health outcomes.
6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations
A young girl in China died after being given an experimental gene therapy intended to treat a neurodevelopmental syndrome, an investigation by Science and Retraction Watch revealed.
Essentia Health looks for volunteer pet therapy teams
Therapy dogs comfort patients, visitors and Essentia staff
When It Comes to Fusion, Materials Matter
Fusion at high temperatures powers the sun and, if harnessed, could provide a potential source of energy here on Earth. But controlling fusion reactions has other benefits. The process also generates subatomic particles called neutrons that are used in a range of applications spanning medicine, research, and national security. Now, scientists at the University of California, Davis (UC Davis), and the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have found that the materials surrounding a fusion reaction can dramatically increase how often it occurs, particularly at low energies where fusion is rare. The study was published July 18 in Nature Communications. Their approach sets up a way to study and engineer nuclear reactions within solid materials, opening a new field of “materials-driven fusion.” Instead of designing materials just to survive the harsh conditions of fusion, researchers might be able to design materials that boost the reaction in specific conditions, similar to the way catalysts speed up chemical processes. “It gives you a new knob to turn that you didn’t have before,” said Arun Persaud, head of the Fusion Science & Ion Beam Technology group in Berkeley Lab’s Accelerator Technology & Applied Physics (ATAP) Division. “If we understand this effect better, it opens the door to engineering new materials that would affect the fusion rate under certain conditions. Someday future progress might enable more compact and efficient neutron generators, which have all kinds of applications, like cargo screening, planetary science, and medical therapy and imaging.” In the experiment, researchers used two different methods to pack deuterium, a heavy form of hydrogen atoms that is often used in fusion, into thin foils of palladium and titanium. They then fired a beam of deuterium ions at the foils at different energies and measured how often fusion happened. Then they compared the rates from the different materials and methods with the “bare” fusion reaction (not in a material). The team found that fusion rates depended on how the deuterium was loaded into the metal foils. The biggest effect was at the lowest energies, below 2.5 kiloelectronvolts (keV), where theory predicts fusion rates drop off sharply. Instead, researchers found a surprising plateau: Some samples showed elevated fusion rates roughly a quintillion times higher than bare fusion reactions. (A quintillion is a 1 followed by 18 zeroes.) Researchers are not exactly sure why that’s happening, though they have some ideas and ways to test them. The electrons and defects within the material might partially shield repulsive electrostatic forces between deuterium nuclei, making it easier for them to get close together and fuse. Tuning the electronic structure, defects, and composition of materials could help make nuclear reactions happen more readily. “It comes down to better understanding the mechanism so that we can try to enhance it,” said corresponding author Jeremy Munday, a professor at UC Davis. “We’ve seen that we can increase fusion rates, but what is the limit? Can we bring it to lower temperatures or energies? There’s obviously a lot of interest and excitement about fusion, so if there’s something we can learn about the physics at these lower energy scales, maybe there’s something we can translate to other areas of nuclear science.” The team plans to explore a wider range of materials and continue probing the unexpected fusion plateau at lower energies. Their work establishes a reproducible experimental platform to study how solid materials influence nuclear reactions, creating a new area of research that links fusion science with materials science and chemistry. “The work shows conclusively that the material environment where fusion occurs at low temperatures is an active participant rather than a passive container,” said Cameron Geddes, director of ATAP. “That adds a new dimension to fusion research.” This work was funded by the U.S. Department of Energy’s Advanced Research Projects Agency-Energy (ARPA-E). ### Lawrence Berkeley National Laboratory (Berkeley Lab) is committed to groundbreaking research focused on discovery science and solutions for abundant and reliable energy supplies. The lab’s expertise spans materials, chemistry, physics, biology, earth and environmental science, mathematics, and computing. Researchers from around the world rely on the lab’s world-class scientific facilities for their own pioneering research. Founded in 1931 on the belief that the biggest problems are best addressed by teams, Berkeley Lab and its scientists have been recognized with 17 Nobel Prizes. Berkeley Lab is a multiprogram national laboratory managed by the University of California for the U.S. Department of Energy’s Office of Science. DOE’s Office of Science is the single largest supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visit energy.gov/science.
FDA sees early promise in new gene therapy for BAG3-associated DCM
An investigational drug therapy from Affinia Therapeutics has secured the FDA's orphan drug designation. This means the company now has access to certain benefits, including tax credits and fee exemptions, as it works toward approval.
New 360 Behavioral Health autism care center opens in Visalia
A new 360 Behavioral Health autism care center is now open in Visalia, bringing Applied Behavior Analysis, or ABA, therapy services closer to families in the Central Valley.
Implementing non-linear periodization in sport rehabilitation
Authors: Parker Joens1,2, Matt Dewald1 1Department of Physical Therapy, University of South Dakota, Vermillion, SD, USA 2Sanford Fieldhouse, Sanford Health, Sioux Falls, SD, USA Correspondin…
Amazon science meets rare disease innovation
A plant-derived therapy rooted in Amazonian medicine is advancing as a potential treatment for rare and life-threatening intestinal failure conditions
Want to dye shirts while sipping wine? Try these new NJ businesses
Tipsy Tie Dye is open at American Dream. JAG Physical Therapy has a new location in Kearny. Precision Surgery Center is in Englewood Cliffs.
New cancer therapy at UVA Health Children’s successfully treats 8-year-old patient
UVA Health Children's is the first hospital to have a successful treatment using CAR T-cell therapy for a pediatric cancer patient.
Pete Hegseth’s Plan for ‘High T’ Troops Is a Junk Science Fever Dream
The defense secretary’s idea of administering testosterone therapy to service members of the US Armed Forces reveals little understanding of the complexity of hormones.
Cornerstone University Launches New Master of Science in Marriage and Family Therapy
Cornerstone University launches a new online M.S. in Marriage and Family Therapy, preparing students for LMFT licensure in Michigan and beyond.
UAMS Opens New Orthopaedic and Sports Medicine Clinic on Rodney Parham in Little Rock
UAMS Celebrates its Newest Orthopaedic and Sports Medicine Clinic featuring traditional therapy, therapy for women, spine therapy and sports performance offerings.
Hegseth announces annual testosterone screenings for service members
Defense Secretary Pete Hegseth on Wednesday announced a new effort to annually screen service members’ testosterone levels and offer testosterone replacement therapy (TRT), framing it as a way to k…
NC families fear losing access to autism therapy as new rules take effect
Parents and providers warn that changes to treatment reauthorization and who can provide autism therapy could mean many children lose care.
New Port Richey cryotherapy business offers specialized treatment for retired K9's
Former working dogs in Pasco County are receiving high-tech medical treatments to ease chronic pain and improve their quality of life after years of service.
Essentia Health opens new clinic in West Duluth
The new location offers care for all ages with sports performance, physical therapy and rehabilitation services.
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
Companion Animal Health CT-RevitL™ Companion Animal Health CT-RevitL™, the next-generation laser therapy system for veterinary care. CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S.
Street therapists struggle to meet growing need for homeless mental health services
LIKE MANY PEOPLE who are or have been homeless, Jessica Scott struggles with debilitating anxiety. When she finally moved from her stepfather’s car into a
Typology Of AI-Based Therapy Micro-Bursts Reveals How People Lean Into Chatbots For Mental Health Advice
I've previously defined AI-based therapy micro-bursts, which is how people tend to use AI for mental health advice. Now, here's my typology. An AI Insider scoop.
The quest to save Grace — and clear the way for rare disease patients everywhere
How a father’s quest may shape the future of rare disease gene therapy.
A Dog Named Dug: The Science Behind Therapy Animals
Through the Cornell Companions program, volunteer therapy animals on campus bring emotional and neurochemical benefits to students during stressful times.
Therapy in a tent: The healthcare many homeless Californians need but aren’t getting
Homeless Californians suffer from depression, anxiety and PTSD at high rates; street therapy can be life changing, but access is limited.
Doc strikes out on her own with hormone therapy practice Lumineux Health near Willow Lawn
An OB/GYN and former partner at Virginia Physicians for Women, Amanda Vaughan said she started Lumineux after seeing a need from women experiencing perimenopause and menopause.
Creatine doesn't just build muscle. It may also help fight cancer
Scientists have discovered that creatine may strengthen one of the immune system's most important cancer-fighting pathways by energizing dendritic cells that activate killer T cells. The promising results could eventually help make immunotherapy more effective, but they have not yet been tested in human patients.
CaroMont Health Opens CaroMont Hematology & Oncology in Belmont
CaroMont Health has opened CaroMont Hematology & Oncology in Belmont, expanding access to cancer and blood disorder care across the region. Located in the CaroMont Health Medical Pavilion on the campus of CaroMont Regional Medical Center in Belmont, the practice offers physician visits, infusion therapy and laboratory services in one convenient location, along with comprehensive hematology and medical oncology care including chemotherapy, immunotherapy, targeted therapy, hormone therapy and survivorship support. The opening is part of CaroMont Health's $200 million investment in cancer care, the second largest investment in the health system's history, which will double its oncology capacity across the region.
Charlotte patients turn to ketamine therapy for mental health treatment
The club drug once known as "Special K" is becoming an unlikely treatment for depression.
Is testosterone therapy a fix for aging? The Trump administration proposes easing prescription rules
Boosting low levels of the hormone is seen as a possible fix for men’s chronic health problems.
Protein lactylation in health and diseases: molecular mechanisms, biological significance, and clinical implications
Signal Transduction and Targeted Therapy - Protein lactylation in health and diseases: molecular mechanisms, biological significance, and clinical implications
AI in Mental Health: Why Clinicians Need to Be in the Room
As clinicians, we learn not to be agreeable, we learn to challenge and sit in discomfort. We ask the hard questions underneath the one being asked. That is the work these tools are not yet built to do.
Marshall Health Network first in West Virginia to offer histotripsy treatment for liver tumors
HUNTINGTON, W.Va. – Marshall Health Network–Cabell Huntington Hospital (CHH) is the first hospital in West Virginia to treat liver tumors using the Edison® Histotripsy System, giving patients access to an advanced treatment that targets tumors with focused sound waves instead of surgery, chemotherapy or radiation. The Edison Histotripsy System uses image-guided sonic beam therapy to precisely target […]
At this Wasilla ranch, horses are part of the mental health care team
An equine-assisted psychotherapy program in Wasilla helps people process trauma, grief and mental health challenges, even if talking isn't easy.
Chatbots Are Replacing Therapists With Little Scientific Evidence Behind Them
Over 100 chatbots are marketed as mental-health-focused, but experts warn they shouldn’t take the place of therapy.
Essentia Health-Duluth Clinic welcomes psychotherapist Jeremy Perrett
Jeremy Perrett, a licensed independent clinical social worker specializing in psychotherapy, is thrilled to join the Essentia Health-Duluth Clinic.
Students in Distress Turning to AI for Mental Health Support, Study Shows
Nearly one in five college students is turning to AI for mental health reasons, and those with severe symptoms are roughly twice as likely to do so.
Sword Health contracted to provide AI-supported physical therapy for an entire country
Portugal's National Health Service signed a deal with digital health company Sword for its AI-assisted virtual physical therapy care.
Life Science Reagent Market Forecast Points Higher Toward 2035, Driven by Biopharma Scale-Up and Cell Therapy Expansion
World life science reagent market forecast 2026-2035: CAGR 6-8%, index 2035=185. Bioprocessing, cell therapy, and QC drive growth. Key players: Thermo Fisher, Merck, Danaher.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
Science & Medicine: Scanning the brain to improve treatment for traumatized teens
Around 20% of teens who have experienced emotional trauma don't respond to talk therapy. UT Health San Antonio is using neuroimaging to track brain changes in traumatized teens during a course of therapy to see if they can figure out why, which could lead to the development of more personalized treatments that will help more teens heal.
TherapyGo Announces Milestone as AI-Powered Mental Health Platform Expands Access to Licensed Psychologists
BOCA RATON, Fla., June 27, 2026 (GLOBE NEWSWIRE) -- United Innovation Solutions LLC today announced a major growth milestone for TherapyGo, its ...
New vitamin B12 therapy shows promise against deadly brain cancer
Researchers have identified a vitamin B12–based compound that can cross the blood-brain barrier and home in on glioblastoma tumors. In animal studies, the compound accumulated preferentially in tumor tissue and delivered sustained nitric oxide directly to cancer cells. It also worked synergistically with existing glioblastoma treatments, significantly enhancing their tumor-fighting effects.
Senators call for military healthcare program to cover autism therapy as a basic benefit
A letter to Defense Secretary Pete Hegseth follows an NBC News investigation into the military healthcare program’s restrictions on applied behavioral therapy.
This autism therapy is covered by many insurers. Why does the military’s plan restrict it?
Logan Cabiao started applied behavior analysis therapy for autism when he was 2. Several years later, TRICARE, the military’s healthcare program, imposed major coverage restrictions.
Health Watch: Scientists say animal therapy helps critically ill patients, prompting new legislation
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
12 arrested in South Florida in nationwide investigation into $6.5B health care fraud
Investigators say Medicaid and Medicare thieves in South Florida bilked taxpayers for $27 million for everything from fake therapy to medical equipment patients never received. Officials seized the stolen taxpayer money from Key West to Fort Pierce.
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
Psychedelic Science 2027 (PS27) convenes May 3–7, 2027, at the Colorado Convention Center in Denver under the theme “Bridging Promise & Practice”PS27’s speaker submission is now open through Friday, September 18, with no planned extensionsPS27 welcomes proposals across science, therapy, policy, culture, industry, the humanities, spirituality, connected movements, and the wisdom traditions that have carried this work for generations DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- The Multidisciplinary